Trade Ideas

Traders Sentiment

Technical Summary



Haleon not a party to U.S. litigation focused on Zantac - spokesperson

By Natalie Grover LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said, responding to Reuters querying a near-20% decline in Haleon's share price this week.

Wall Street Journal - August 9

Aug 9 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - As Kewsong Lee's five-year contract was drawing to a close, advisers to Carlyle Group Inc's CG.O CEO worked with representatives of the buyout firm to prepare an initial proposal for a new deal but the contract proposal never got a response from Carlyle's board.

Biden again tests positive for 19, feels 'quite well' - White House

(Recasts top) By Jarrett Renshaw and Pete Schroeder WASHINGTON, July 30 (Reuters) - U.S. President Joe Biden tested positive for COVID-19 again on Saturday morning in what the White House doctor describes as a "rebound" case seen in a small percentage of patients who take the antiviral drug Paxlovid. Biden, 79, who emerged from COVID isolation on Wednesday after testing positive on July 21, will now return to strict isolation and will cancel planned trips to his home in Wilmington and work trip

New York Times business news - July 29

July 29 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Instagram META.O said it was rolling back several recent updates to its photo-sharing app after Kylie Jenner and other celebrities joined a user backlash against the changes and criticized the platform for trying to be too much like TikTok.

Financial Times - July 22

July 22 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Pfizer and Flynn fined 70 mln stg by UK regulator for epilepsy drug price rises Link - EDF pushes UK government to alter Hinkley Point C penalty clauses Link - Tata threatens to close Port Talbot steelworks without 1.5 bln stg of aid Link - Marks and Spencer finance chief to depart retailer and join Primark owner ABF Link Overview


Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.